2.26 USD
▲+0.06+5.12%
盘后 2.13 -0.93%
2026-08-03
市值
$161.69M
市盈率
—
EPS
-1.35
股息率
—
52 周区间
1.70 – 3.72
成交量
750.84K
Beta
0.94
目标价
11.33
52W 低 1.7052W 高 3.72
价格走势
公司简介
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The com...